MarketInOut Stock Screener Log In | Sign Up

BridgeBio Oncology Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
BridgeBio Oncology Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization216.47 mln
Float45.23 mln
Earnings Date11/18/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

23.55
Transformational upside

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.01
Debt-free

ROE

-52.26
Deeply negative

ROA

-47.29
Deeply negative

Business Description

BridgeBio Oncology Therapeutics is a clinical-stage biotech company focused on developing oral drug treatments for several types of cancer, including lung, breast, and colorectal cancers. The company is advancing multiple drug candidates through early-stage clinical trials, each designed to target specific genetic mutations that drive tumor growth. Founded in 2016 and based in South San Francisco, California, BridgeBio Oncology aims to deliver more precise treatment options for cancer patients with limited alternatives.

Key Fundamentals

EPS-0.07
ROE-52.26
ROIC-188
ROA-47.29
EBITDA, mln-181
EV / EBITDA3.41
EV / EBIT3.39

Quote Details

Last 2.62
Change -0.08 (-2.96%)
Open 2.70
Volume 314,785
Turnover 824,737
Average Volume 581,152

Financial Ratios

Leverage Ratio1.17
Current Ratio4.69
Price / Book0.67
Price / Tangible Book0.67
Debt / Equity0.01

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price23.55
Short Ratio6.51
Short % of Float13.47

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.5% 32 / 100   
1 Month -33.5% 10 / 100   
2 Months -70.06% 3 / 100   
6 Months -68.77% 7 / 100   
1 Year -77.36% 10 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog